7,773
Views
5
CrossRef citations to date
0
Altmetric
Meta-analysis

Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis

, , , , , , , , & show all
Pages 155-166 | Received 13 Apr 2021, Accepted 16 Jun 2021, Published online: 02 Jul 2021

Figures & data

Table 1. PICOS Criteria

Figure 1. PRISMA Flow Diagram.

Figure 1. PRISMA Flow Diagram.

Figure 2. Network of Evidence.

Figure 2. Network of Evidence.

Figure 3. Baseline characteristics of the trials included in the evidence base.

Figure 3. Baseline characteristics of the trials included in the evidence base.

Table 2. Raw Efficacy and Safety Data by Study and Outcome used in the Analysis/Model

Figure 4. Network meta-analysis results for efficacy (treatment vs. placebo).

Figure 4. Network meta-analysis results for efficacy (treatment vs. placebo).

Table 3. Results of fixed-effect models for pain relief and pain freedom at various intervals

Figure 5. Network meta-analysis results for freedom from outcomes: fixed-effects models.

Figure 5. Network meta-analysis results for freedom from outcomes: fixed-effects models.

Figure 6. Network meta-analysis results for safety.

Figure 6. Network meta-analysis results for safety.

Table 4. Surface under the cumulative ranking curve (SUCRA)

Supplemental material

Supplemental Material

Download Zip (108 KB)